{"entity":{"id":"greenwich-lifesciences","kind":"company","name":"Greenwich LifeSciences","aka":["Greenwich LifeSciences, Inc.","NASDAQ:GLSI"],"tldr":"Greenwich LifeSciences is a Texas biotech running a phase 3 trial of GLSI-100, a HER2 peptide vaccine given after standard treatment to stop breast cancer coming back.","summary":"Greenwich LifeSciences develops GLSI-100, a combination of the HER2-derived peptide GP2 with the immune adjuvant GM-CSF, as an immunotherapy to prevent recurrence in HER2-positive breast cancer after surgery and trastuzumab. In a phase 2b trial, HER2-positive patients who completed the full vaccine course had no recurrences over five years. The phase 3 FLAMINGO-01 trial is enrolling HER2-positive patients with residual disease after neoadjuvant therapy.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.greenwichlifesciences.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["glsi-100"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Stafford, Texas","country":"US","companyType":"biotech","website":"https://www.greenwichlifesciences.com/","ticker":"NASDAQ:GLSI","founded":2006,"stage":"public","investors":[],"funding":[]},"route":"/companies/greenwich-lifesciences/","neighbours":{"drug":[{"id":"glsi-100","kind":"drug","name":"GLSI-100","route":"/drugs/glsi-100/"}]}}